3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Thoracic
2
Breast
2
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
6
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
18
Nivolumab
6
Radiotherapy
5
Paclitaxel
5
Trastuzumab
4
Specimen Handling
4
Ipilimumab
4
tisotumab vedotin
3
temsirolimus
3
olaparib
3
lenvatinib
3
X-Rays
3
Taxes
3
Surveys and Questionnaires
3
Early Intervention, Educational
3
Cyclophosphamide
3
Carboplatin
3
Biopsy
3
spartalizumab
2
sargramostim
2
rucaparib
2
palbociclib
2
fludarabine
2
epacadostat
2
enzalutamide
2
durvalumab
2
cabozantinib
2
atezolizumab
2
aflibercept
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
AZD5305
×
Genitourinary
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled